Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786135 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1 study of Burkitt Lymphoma and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT01786135: Completed Phase 1 study of Burkitt Lymphoma and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen.
NCT01786135 is a Phase 1 study of Burkitt Lymphoma and Lymphoma, Large B-Cell, Diffuse that has completed, run by Seagen. The registered enrollment target is 64 participants, below the 74-participant average among 22 other Burkitt Lymphoma trials with a reported enrollment target (14% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01786135, a Phase 1 study of Burkitt Lymphoma and Lymphoma, Large B-Cell, Diffuse, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
Conditions Studied
Interventions
- DRUG SGN-CD19A
Study Locations (6)
California
- City of Hope National Medical Center - Duarte
- Stanford Cancer Center - Stanford
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center / University of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-02-16 |
| Phase | Phase 1 |
What the finished NCT01786135 record still lists
NCT01786135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 74-participant average among 22 other Burkitt Lymphoma trials with a reported enrollment target (14% lower).
The record links to 5 conditions, with Burkitt Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SGN-CD19A is the first listed.
NCT01786135 lists 6 locations in 5 states (California, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT01786135 about?
NCT01786135 is a clinical study titled "A Safety Study of SGN-CD19A for B-Cell Lymphoma". This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
What is the current status of trial NCT01786135?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-02. Estimated completion is 2017-02-16.
What conditions does trial NCT01786135 study?
This clinical trial studies the following conditions: Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
What interventions are being tested in trial NCT01786135?
The interventions under investigation include: SGN-CD19A (DRUG).
Who is sponsoring clinical trial NCT01786135?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01786135 being conducted?
This trial has 6 study locations across Alabama, California, Florida, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burkitt Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01786135's enrollment target sits among peer trials
64 7th of 22 higher than 16 of 22 other Burkitt Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burkitt Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Study of SGR-1505 in Mature B-Cell Neoplasms
RECRUITING · Phase 1
-
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RECRUITING · Phase 1
-
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia